Australia TGA Readiness: AUST L, Permitted Indications and PIC/S PE 009 GMP
Australia does not have a 'dietary supplement' category.
In Short
- Section 26A of the Therapeutic Goods Act 1989 creates the Listed Medicines pathway.
- The Therapeutic Goods (Permissible Ingredients) Determination is updated annually and lists every active and excipient ingredient that may be used in an AUST L…
- The Therapeutic Goods (Permitted Indications) Determination 2018 contains the ~1,000 indications a sponsor may select from for AUST L self-listing.
What Americans call a supplement and Canadians call an NHP, Australia calls a complementary medicine, regulated under the Therapeutic Goods Act 1989 by the Therapeutic Goods Administration (TGA). A low-risk complementary medicine is electronically Listed on the Australian Register of Therapeutic Goods (ARTG) — the sponsor self-certifies against the Permissible Ingredients Determination, the Permitted Indications Determination and the Required Advisory Statements (RASML). The product carries an AUST L number on the label. Higher-risk products move to AUST L(A) (assessed listed) or AUST R. Manufacturing must comply with PIC/S PE 009 GMP, enforced by TGA inspection. This guide maps the AUST L gate, the post-market compliance review risk, and the PE 009 GMP a sponsor must hold.
AUST L vs AUST L(A) vs AUST R — picking the right ARTG pathway
Section 26A of the Therapeutic Goods Act 1989 creates the Listed Medicines pathway. AUST L is electronic self-listing for low-risk complementary medicines whose ingredients are all on the Therapeutic Goods (Permissible Ingredients) Determination and whose indications are all on the Therapeutic Goods (Permitted Indications) Determination.
More on aUST L vs AUST L(A) vs AUST R — picking the right ARTG pathway
The sponsor certifies compliance and the ARTG entry is generated immediately — no pre-market efficacy review. AUST L(A) (introduced 2018) is for sponsors who want to make a non-permitted indication and accept TGA assessment of the efficacy evidence. AUST R is full registration with quality, safety and efficacy review — the path for higher-risk products including most herbal medicines with disease-treatment claims. Picking the wrong pathway is the most expensive avoidable error: an AUST L self-listing with a non-permitted indication will be cancelled at TGA compliance review, with the product withdrawn from sale.
Permissible Ingredients Determination — the only ingredients you can self-list
The Therapeutic Goods (Permissible Ingredients) Determination is updated annually and lists every active and excipient ingredient that may be used in an AUST L medicine, with conditions (concentration limits, route restrictions, warnings, equivalent-amount rules for botanical extracts). An ingredient not on the Determination cannot be self-listed — the sponsor either applies to add it (typically a multi-year evidence dossier), pursues AUST L(A) or AUST R, or reformulates.
More on permissible Ingredients Determination — the only ingredients you can self-list
The Determination also drives mandatory equivalent-amount labelling for herbal extracts (the dry herb equivalent and the actives), and pegs warning statements via RASML to specific ingredients (e.g., kava, comfrey, ephedra-containing).
Permitted Indications and the post-market compliance review
The Therapeutic Goods (Permitted Indications) Determination 2018 contains the ~1,000 indications a sponsor may select from for AUST L self-listing. Each is paired with a level of evidence (traditional or scientific) and may carry a mandatory qualifier (e.g., 'traditionally used in Western herbal medicine').
More on permitted Indications and the post-market compliance review
TGA's Post-Market Review programme samples AUST L medicines and verifies the held evidence supports the listed indications. Compliance review findings cluster on three themes: indications not held in the file, evidence weaker than the Determination requires, and label claims drifting beyond the Permitted Indications wording (especially on websites and social, which the TAC and the Therapeutic Goods Advertising Code 2021 explicitly cover). A failed review can trigger cancellation, infringement notice or court action.
PIC/S PE 009 GMP — what the TGA inspector actually checks
Australian manufacturing licences for medicines are issued under section 35 of the Act and require compliance with the PIC/S Guide to Good Manufacturing Practice for Medicinal Products (PE 009-17). For complementary medicines the relevant annexes are typically Annex 7 (herbal medicinal products), Annex 8 (sampling of starting and packaging materials) and Annex 15 (qualification and validation).
More on pIC/S PE 009 GMP — what the TGA inspector actually checks
Overseas manufacturers supplying the Australian market must hold either a TGA GMP Clearance based on a recognised foreign regulator's inspection (under the MRA, MoU or CV pathway) or a TGA-conducted inspection. The hot zones at recent TGA inspections: data integrity in laboratory systems, stability data not bracketing labelled shelf-life, contamination control at the dispense booth for herbal raw materials, and supplier qualification for botanical actives.
A 120-Day Australian Readiness Path
- Days 1–15
pathway gate — AUST L vs AUST L(A) vs AUST R per SKU, with Permissible Ingredients and Permitted Indications check.
- Days 16–35
ARTG self-listing for AUST L SKUs, AUST L(A) evidence assembly for those that need it.
- Days 36–60
RASML and Therapeutic Goods Advertising Code label and marketing-claim review.
- Days 61–90
PIC/S PE 009 GMP evidence pack — Annex 7 herbal, Annex 8 sampling, Annex 15 validation, plus data-integrity walkthrough.
- Days 91–110
TGA GMP Clearance or domestic licence amendment.
- Days 111–120
mock TGA post-market compliance review.
Questions
What does an AUST L number mean?
AUST L is the identifier for an electronically Listed complementary medicine on the ARTG. The sponsor self-certified that every ingredient is on the Permissible Ingredients Determination and every indication is on the Permitted Indications Determination. There is no pre-market TGA efficacy review — compliance is verified post-market.
Can I make any health claim on an AUST L product?
No. AUST L sponsors must select indications from the Permitted Indications Determination 2018. A non-permitted indication requires AUST L(A) with TGA evidence assessment, or AUST R full registration. Marketing claims (including social media) are also bound by the Therapeutic Goods Advertising Code 2021.
Do I need an Australian manufacturer?
No, but every manufacturing site (overseas or domestic) supplying the Australian market must hold either an Australian GMP Licence or a TGA GMP Clearance based on a recognised foreign regulator's inspection. PIC/S PE 009 is the operative GMP standard.
What triggers a TGA post-market review?
Risk-based sampling, complaints, advertising compliance signals, and targeted reviews of high-risk ingredient classes. A review checks the sponsor's held evidence against the listed indications, the label against RASML, and the manufacturing GMP against PE 009.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Dietary Supplement Operations Guide
What the label says. What the batch proves.
- The rules and who decides
- Specification to finished batch
- Test, review, investigate
- Labels, samples and recall
Plus Evidence map and four worksheets.
Get the supplement guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Dietary Supplement Operations Guide
What the label says. What the batch proves.
Keep reading
Australian Listed Medicines: What the Sponsor Certifies Under Section 26A
Australia AICIS Industrial Chemicals: Introducer Obligations
Australia APVMA Agvet Chemicals: Registration and Licensing
Australia Medical Device Regulatory Readiness Guide
Australia and NZ Supermarket Supplier Standards Guide
Australia Pharmaceutical GMP Readiness: TGA and PIC/S GMP